Bayer to spend $20m to correct misleading advertising for oral contraceptive YazBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b674 (Published 17 February 2009) Cite this as: BMJ 2009;338:b674
- Janice Hopkins Tanne
- 1New York
Bayer Healthcare Pharmaceuticals has agreed to spend $20m (£14m; €15.6m) to correct misleading direct to consumer advertising of its birth control pill Yaz (drospirenone and ethinylestradiol), the most popular birth control pill in the United States, with sales of about $616m last year.
The corrective advertisements began running last month and will continue through June, the US Food and Drug Administration (FDA) said.
Bayer reached an agreement with the FDA and 27 state attorneys general, led by Bill McCollum, the Florida attorney general. The agreement follows a warning letter sent to Bayer in October by Thomas Abrams, the director of the FDA’s division of drug marketing, advertising, and communications. It adds new requirements to a 2007 agreement about problems related to Bayer’s non-disclosure of safety risks associated …
Log in using your username and password
Log in through your institution
Sign up for a free trial